TAO Synergies TAOX
NASDAQ TAOX
$4.07 +0.06 (+1.50%)
As of: Sep 9, 2026 · 11:20 AM EDT

TAO Synergies (TAOX) Income from Continuing Operations (2019 - 2026)

TAO Synergies' (TAOX) quarterly Income from Continuing Operations came in at -$9.3 million in Q2 2026, up 46.91% on a YoY basis from -$6.3 million in Q2 2025, and down 318.57% quarter-over-quarter from $4.3 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Income from Continuing Operations (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Income from Continuing Operations for 8 consecutive years, with -$9.3 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income from Continuing Operations rose 46.91% year-over-year to -$9.3 million; the trailing twelve-month figure through Jun 2026 stood at -$16.7 million (up 41.41% YoY), and the FY2025 full-year result was -$22.7 million, down 125.06% from the prior year.
  • Income from Continuing Operations eased to -$9.3 million in Q2 2026 per TAOX's latest filing, from $4.3 million in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at $4.5 million in Q4 2022 and bottomed at -$17.5 million in Q2 2025.
  • Historically, Income from Continuing Operations has averaged -$3.2 million across 5 years, with a median of -$3.2 million in 2022.
  • The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 1275.63% in 2025, then soared 1004.55% in 2026.
  • Over 5 years, Income from Continuing Operations stood at $4.5 million in 2022, then tumbled by 122.22% to -$995969.0 in 2023, then sank by 456.9% to -$5.5 million in 2024, then sank by 38.52% to -$7.7 million in 2025, then declined by 21.03% to -$9.3 million in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered -$9.3 million, $4.3 million, and -$7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 212.35 Bn 198.36 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 181.19 Bn 178.01 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.48 Bn 124.62 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.59 Bn 74.60 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.45 Bn 56.27 Bn 1.37 Bn 601.00 Mn
6 Moderna 54.89 Bn 49.75 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.21 Bn 30.90 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.38 Bn 30.10 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.81 Bn 29.81 Bn 1.16 Mn -290.61 Mn
10 TAO Synergies 30.41 Mn 30.41 Mn - -9.30 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -9.30 Mn
Mar 31, 2026 4.25 Mn
Dec 31, 2025 -7.68 Mn
Sep 30, 2025 -3.92 Mn
Jun 30, 2025 -17.52 Mn
Mar 31, 2025 385,169.00
Dec 31, 2024 -5.55 Mn
Sep 30, 2024 -5.74 Mn
Jun 30, 2024 -1.27 Mn
Mar 31, 2024 -206,699.00
Dec 31, 2023 -995,969.00
Sep 30, 2023 763,203.00
Jun 30, 2023 -4.09 Mn
Mar 31, 2023 -1.71 Mn
Dec 31, 2022 4.48 Mn
Sep 30, 2022 -3.03 Mn
Jun 30, 2022 -3.75 Mn
Mar 31, 2022 -3.28 Mn
Dec 31, 2021 -4.24 Mn
Sep 30, 2021 -2.93 Mn